Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001890 · ClinicalTrials.gov registry record · Phase 2
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
A Phase 2 study of Atherosclerosis and Cytomegalovirus Infections, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00001890: Completed Phase 2 study of Atherosclerosis and Cytomegalovirus Infections, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00001890 is a Phase 2 study of Atherosclerosis and Cytomegalovirus Infections that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 80 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001890, a Phase 2 study of Atherosclerosis and Cytomegalovirus Infections, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases. These findings suggest that estrogen may be protective and help in preventing heart disease. Studies of large groups of post-menopausal women suggest that hormone replacement therapy (therapy that includes estrogen) reduces the risk of heart disease. Estrogen causes favorable changes in particles that carry cholesterol in the blood stream and improves function of blood vessels. Estrogen may also stimulate the immune system's ability to fight off infections that may lead to or contribute to atherosclerosis. Researchers believe two specific infectious agents (Chlamydia pneumoniae and human cytomegalovirus) may cause damage to the lining of blood vessels resulting in inflammation and the development of atherosclerosis. The purpose of this study is to determine if estrogen treatment can change how the immune system responds to chronic infections, by Chlamydia pneumoniae and human cytomegalovirus, in postmenopausal women.
Conditions Studied
Interventions
- DRUG Estrogen therapy
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 1999-05 |
| Est. Completion | 2001-03 |
| Phase | Phase 2 |
What the finished NCT00001890 record still lists
NCT00001890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which Estrogen therapy is the first listed.
NCT00001890 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001890 about?
NCT00001890 is a clinical study titled "Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections". Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases. These findings suggest that estrogen may be protective and help in preventin...
What is the current status of trial NCT00001890?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 1999-05. Estimated completion is 2001-03.
What conditions does trial NCT00001890 study?
This clinical trial studies the following conditions: Atherosclerosis, Cytomegalovirus Infections, Postmenopause, Pneumonia, Bacterial, Chlamydia Infections.
What interventions are being tested in trial NCT00001890?
The interventions under investigation include: Estrogen therapy (DRUG).
Who is sponsoring clinical trial NCT00001890?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001890 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001890's enrollment target sits among peer trials
80 56th of 69 higher than 14 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Advancing Postmenopausal Preventive Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
COMPLETED · Phase 2
-
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
COMPLETED · Phase 2
-
VEAPS: Vitamin E Atherosclerosis Prevention Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia